scholarly journals Effect of transcutaneous electrical nerve stimulation on vertebral metastatic bone pain of breast cancer patients: single case experimental study

Revista Dor ◽  
2016 ◽  
Vol 17 (2) ◽  
Author(s):  
Luciana Ribeiro Sampaio ◽  
Marcos Antonio de Resende ◽  
Leani Souza Maxima Pereira
Keyword(s):  
Breast Cancer ◽  
Experimental Study ◽  
Cancer Patients ◽  
Nerve Stimulation ◽  
Transcutaneous Electrical Nerve Stimulation ◽  
Bone Pain ◽  
Single Case ◽  
Breast Cancer Patients ◽  
Electrical Nerve Stimulation ◽  
Metastatic Bone Pain

Antiemetic efficacy of transcutaneous electrical nerve stimulation (TENS) at pericardium 6 acupuncture point (P6) in the treatment of chemotherapy-induced delayed nausea and vomiting (CINV) in stage I to III breast cancer patients during adjuvant/neoadjuvant chemotherapy (Ad/nAd).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. TPS648-TPS648
Author(s):  
Jean Yared ◽  
Melody Hu ◽  
Ting Bao ◽  
Saranya Chumsri ◽  
Emily Catherine Bellavance ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Nerve Stimulation ◽  
Transcutaneous Electrical Nerve Stimulation ◽  
Lateral Side ◽  
Breast Cancer Patients ◽  
Electrical Nerve Stimulation ◽  
Delayed Nausea ◽  
Stage 1 ◽  
Self Stimulation

TPS648 Background: CINV remain major adverse effects of highly emetic chemotherapy for breast cancer patients (BC). Patients (PT) rate nausea & vomiting as the most feared chemotherapy-related symptoms. There is substantial evidence that P6 (located in the region in the middle of the wrist 3 finger breaths from the juncture of the hand & wrist) acupuncture is an effective antiemetic treatment in a variety of PT including the post-anesthesia, obstetrical, and motion sickness PT. We hypothesized that application of TENS at P6 point will reduce:1) the overall incidence of CINV episodes in stage 1-3 BC PT, 2) the severity & duration of CINV, 3) the requirement for rescue antiemetics 4) & that TENS is well tolerated & feasible. Maxima III Transcutaneous Electrical Nerve Stimulation unit is utilized in this study & is self-administered by PT. Patients and Methods: We are conducting a prospective, randomized, double-blinded, controlled trial to determine if self-stimulating P6 may decrease the incidence and severity of delayed CINV in stage 1-3 BC treated with the initial dose of highly emetic Ad/nAd (AC, AC-T, TAC, TC, TCH) and reduce PT' need for rescue oral antiemetic medications. PT will be randomized in a 1:1 ratio to the active treatment group (TENS self-stimulation at P6) & the control group (TENS self-stimulation at a point on the lateral side of the elbow that does not conform to any known acupuncture points). The assignments are blinded to the PT & the investigators. Subjects self-administer TENS at home q4 hours for 20 minutes during days 2-5 postchemotherapy. The use of conventional antiemetic therapy (corticosteroids, setrons, aprepitant, phenergan & prochlorperazine) is similar for both treatment groups. The severity of nausea symptoms, episodes of emesis, use of rescue antiemetics, and compliance are recorded daily by the PT in diaries. A brief questionnaire is also administered to evaluate PT tolerability of TENS & their ability to comply with the treatment regimen. Twenty six out of 70 planned PT have been enrolled. Recruitment is ongoing.

Metastatic bone pain palliation with 89‐Sr and 186‐Re‐HEDP in breast cancer patients

2001 ◽  
Vol 66 (2) ◽  
pp. 101-109 ◽  
Author(s):  
Rosa Sciuto ◽  
Anna Festa ◽  
Rosella Pasqualoni ◽  
Alessandro Semprebene ◽  
Sandra Rea ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Bone Pain ◽  
Pain Palliation ◽  
Breast Cancer Patients ◽  
Bone Pain Palliation ◽  
Metastatic Bone Pain

186Re-HEDP for Metastatic Bone Pain in Breast Cancer Patients

Breast Cancer ◽  
2008 ◽  
pp. 257-269
Author(s):  
Marnix G. E. H. Lam ◽  
John M. H. de Klerk ◽  
Peter P. van Rijk
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Bone Pain ◽  
Breast Cancer Patients ◽  
Metastatic Bone Pain

186Re-HEDP for metastatic bone pain in breast cancer patients

2004 ◽  
Vol 31 (S1) ◽  
pp. S162-S170 ◽  
Author(s):  
Marnix G. E. H. Lam ◽  
John M. H. de Klerk ◽  
Peter P. van Rijk
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Bone Pain ◽  
Breast Cancer Patients ◽  
Metastatic Bone Pain

Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.

1998 ◽  
Vol 16 (12) ◽  
pp. 3890-3899 ◽  
Author(s):  
J J Body ◽  
R Bartl ◽  
P Burckhardt ◽  
P D Delmas ◽  
I J Diel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Multiple Myeloma ◽  
Cancer Patients ◽  
Bone Pain ◽  
Objective Response ◽  
Metastatic Breast ◽  
Morbidity Rate ◽  
Duration Of Treatment ◽  
Analgesic Effects ◽  
Metastatic Bone Pain

PURPOSE The purpose of this article is to review the recent data on bisphosphonate use in oncology and to provide some guidelines on the indications for their use in cancer patients. DESIGN The group consensus reached by experts on the rationale for the use of bisphosphonates in cancer patients and their current indications for the treatment of tumor-induced hypercalcemia and metastatic bone pain in advanced disease and for the prevention of the complications of multiple myeloma and of metastatic bone disease are reviewed. RESULTS Bisphosphonates are potent inhibitors of tumor-induced osteoclast-mediated bone resorption. They now constitute the standard treatment for cancer hypercalcemia, for which we recommend a dose of 1,500 mg of clodronate or 90 mg of pamidronate; the latter compound is more potent and has a longer lasting effect. Intravenous bisphosphonates exert clinically relevant analgesic effects in patients with metastatic bone pain. Regular pamidronate infusions can also achieve a partial objective response by conventional International Union Against Cancer criteria and enhance the objective response rate to chemotherapy. In breast cancer, the prolonged administration of oral clodronate 1,600 mg daily reduces the frequency of morbid skeletal events by more than one fourth, whereas monthly pamidronate infusions of 90 mg for only 1 year in addition to chemotherapy reduce by more than one third the frequency of all skeletal-related events. The use of bisphosphonates to prevent bone metastases remains experimental. Last, bisphosphonates in addition to chemotherapy are superior to chemotherapy alone in patients with stages II and III multiple myeloma and can reduce the skeletal morbidity rate by approximately one half. CONCLUSION Bisphosphonate use is a major therapeutic advance in the management of the skeletal morbidity caused by metastatic breast cancer or multiple myeloma, although many questions remain unanswered, notably regarding the optimal selection of patients and the duration of treatment.

scholarly journals Application of a domicile-based exercise program for shoulder rehabilitation after breast cancer surgery

2012 ◽  
Vol 20 (1) ◽  
pp. 35-43 ◽  
Author(s):  
Eliana Louzada Petito ◽  
Afonso Celso Pinto Nazário ◽  
Simone Elias Martinelli ◽  
Gil Facina ◽  
Maria Gaby Rivero De Gutiérrez
Keyword(s):  
Breast Cancer ◽  
Experimental Study ◽  
Cancer Patients ◽  
Preoperative Evaluation ◽  
Exercise Program ◽  
Breast Cancer Surgery ◽  
Breast Cancer Patients ◽  
Quasi Experimental ◽  
Study Population

The aim of this study was to evaluate the effectiveness of an exercise program for the recuperation of the range of motion (ROM) of the shoulder. This is a quasi-experimental study developed at the Mastology Outpatient Clinic of the Federal University of São Paulo - Brazil, from August 2006 to June 2008, with 64 breast cancer patients undergoing surgery. The intervention consisted of: preoperative evaluation of the ROM, verbal and written guidance, demonstration and implementation of the exercises and revaluation at the outpatient follow-up appointments until the 105th postoperative day (PO). From the 7th PO a significant increase was observed in the ROM, which continued until the 105th PO. The minimum time for recovery was 105 days for the women undergoing mastectomy, and 75 days for those undergoing quadrantectomy. There was satisfactory adherence of 78.6% of the women. The domicile program was effective for the recovery of ROM in the study population, benefiting women who can not attend a presential program.

Sign in / Sign up

Export Citation Format

Share Document